Ina Brandes, Minister for Science and Culture of the State of North Rhine-Westphalia, included: “With AI4CancerCure.NRW, we are developing a protected data space and, through the use of AI, methodically interlinking cancer biology, data-driven drug design, imaging- and data-based diagnostics, and the rapid advancement of medical products. The outcome is concrete advantages for patients. It will be possible to detect cancer previously, projection disease development more precisely and offer tailored treatment with far fewer adverse effects. In addition, patients will be regularly involved in the research study process on the structural level– since successful cancer research can only be accomplished hand in hand with those impacted.”
New active substances and personalized avoidance
New drugs and the continuous development of cancer prevention are among the most crucial difficulties dealing with contemporary medicine. Apart from facilitating individualized avoidance and early detection, AI and data-driven approaches can substantially accelerate the identification, advancement and medical testing of brand-new active compounds. To this end, AI4CancerCure.NRW will bundle existing expertise in oncology, artificial intelligence, drug advancement, imaging, information science and medical research.
Researchers at TU Dortmund University will contribute their know-how in AI and drug discovery, working specifically in the following locations: AI-supportedthe development and optimization of small particles as drug precursors, their chemical and biological characterization and home prediction, synthesis, and process development, consisting of lab automation. “Thanks to close networking within AI4CancerCure.NRW, it will be possible to integrate main medical information straight into drug design,” states Professor Stefan M. Kast, task planner for TU Dortmund University at the Department of Chemistry and Chemical Biology. EUR25 million have been assigned to TU Dortmund University, which it has actually allocated for computer system and lab facilities, for instance.
Taking part in the consortium along with TU Dortmund University are the university healthcare facilities in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne (speaker university) and Münster. The purpose of the “North Rhine-Westphalia Plan for Good Infrastructure”, from which a total of EUR2.3 billion are offered for higher education, university medicine and research study, is to finance investments in the major problems of tomorrow. It should also enhance and advance North Rhine-Westphalia as a center for research study and science in the long term.
Contact for queries: